Journal of the American Academy of Dermatology
Volume 63, Issue 1 , Pages 114-123 , July 2010

Factors affecting sleep quality in patients with psoriasis

  • Smitha Gowda, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland
    • ,
  • Orin M. Goldblum, MD

      Affiliations

    • Abbott Laboratories, Abbott Park, Illinois
    • ,
  • W. Vaughn McCall, MD, MS

      Affiliations

    • Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Steven R. Feldman, MD, PhD

      Affiliations

    • Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • Corresponding Author InformationCorrespondence to: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071.

References 

  1. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54:685–704
  2. Mukhtar R, Choi J, Koo JY. Quality-of-life issues in psoriasis. Dermatol Clin. 2004;22:389–395viii
  3. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–496
  4. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–284
  5. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(Suppl):S57–S61
  6. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140–147
  7. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407
  8. Duffin KC, Wong B, Horn EJ, Krueger GG. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol. 2009;60:604–608
  9. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7:373–377
  10. Wong B, Horn EJ, Krueger GG, Duffin KPC. Predictors of sleep disturbance in patients with psoriasis. J Investig Dermatol. 2008;128:S82
  11. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol. 1990;123:751–756
  12. Delfino M, Holt EW, Taylor CR, Wittenberg E, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol. 2008;59:439–447
  13. Hu SW, Holt EW, Husni ME, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot study Semin Arthritis Rheum doi:10.1016/j.semarthrit.2008.10.005. Published online December 16, 2008.
  14. Reich A, Szepietowski JC. Mediators of pruritus in psoriasis. Mediators Inflamm. 2007;2007:64727
  15. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969–973
  16. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151:594–599
  17. Szepietowski JC, Reich A, Wisnicka B. Pruritus and psoriasis. Br J Dermatol. 2004;151:1284
  18. Savin JA, Paterson WD, Oswald I, Adam K. Further studies of scratching during sleep. Br J Dermatol. 1975;93:297–302
  19. Savin JA, Adam K, Oswald I, Paterson WD. Pruritus and nocturnal wakenings. J Am Acad Dermatol. 1990;23:767–768
  20. Bender BG, Ballard R, Canono B, Murphy JR, Leung DY. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol. 2008;58:415–420
  21. Chamlin SL, Mattson CL, Frieden IJ, Williams ML, Mancini AJ, Cella D, et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med. 2005;159:745–750
  22. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, Sampson HA, Lupo M. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med. 1995;149:856–860
  23. Aoki T, Kushimoto H, Hishikawa Y, Savin JA. Nocturnal scratching and its relationship to the disturbed sleep of itchy subjects. Clin Exp Dermatol. 1991;16:268–272
  24. Gupta MA, Gupta AK, Ellis CN, Voorhees JJ. Some psychosomatic aspects of psoriasis. Adv Dermatol. 1990;5:21–30
  25. Gupta MA, Gupta AK, Kirkby S, Schork NJ, Weiner HK, Ellis CN, et al. Pruritus associated with nocturnal wakenings: organic or psychogenic?. J Am Acad Dermatol. 1989;21:479–484
  26. Amatya B, Wennersten G, Nordlind K. Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22:822–826
  27. Zachariae R, Zachariae CO, Lei U, Pedersen AF. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm Venereol. 2008;88:121–127
  28. Wong B, Downing T, Simpson R, Krueger GG, Duffin KC. Polysomnography of patients with psoriasis show prolonged stage I sleep and lower oxygen levels compared to controls. J Investig Dermatol. 2009;129:S53
  29. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14:267–271
  30. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23:681–694
  31. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–392
  32. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215:17–27
  33. Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: a comparative study. J Dermatol. 2001;28:419–423
  34. Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol. 2002;16:347–352
  35. Schmitt J, Ford DE. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis–a structural equations modeling approach. Gen Hosp Psychiatry. 2007;29:134–140
  36. Evers AW, Lu Y, Duller P, van der Valk PG, Kraaimaat FW, van de Kerkhof PC. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152:1275–1281
  37. Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, et al. Pruritus in psoriasis: a prospective study of some psychiatric and dermatologic correlates. Arch Dermatol. 1988;124:1052–1057
  38. Gupta MA, Gupta AK, Schork NJ, Ellis CN. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med. 1994;56:36–40
  39. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411–418
  40. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005;66:1254–1269
  41. Argyropoulos SV, Wilson SJ. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry. 2005;17:237–245
  42. Mostaghimi L. Prevalence of mood and sleep problems in chronic skin diseases: a pilot study. Cutis. 2008;81:398–402
  43. National Psoriasis Foundation. 2008 Survey panel snapshot. Available from: URL:http://www.psoriasis.org/files/pdfs/research/2008_fall_survey_panel.pdf. Accessed April 8, 2009.
  44. Silva A, Andersen ML, Tufik S. Sleep pattern in an experimental model of osteoarthritis. Pain. 2008;140:446–455
  45. Onen SH, Onen F, Courpron P, Dubray C. How pain and analgesics disturb sleep. Clin J Pain. 2005;21:422–431
  46. Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and pain perception. Sleep Med Rev. 2006;10:357–369
  47. Buslau M, Benotmane K. Cardiovascular complications of psoriasis: does obstructive sleep apnea play a role?. Acta Derm Venereol. 1999;79:234
  48. Yang XQ, You L, Zhang-Rui J. Study of sleep quality in patients with psoriasis. J Investig Dermatol. 2007;127:1809
  49. Parati G, Lombardi C, Narkiewicz K. Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk. Am J Physiol Regulatory Integrative Comp Physiol. 2007;293:R1671–R1683
  50. Sun X, Yi H, Cao Z, Yin S. Reorganization of sleep architecture after surgery for OSAHS. Acta Otolaryngol. 2008;128:1242–1247
  51. Malhotra A, White DP. Obstructive sleep apnea. Lancet. 2002;360:237–245
  52. McArdle N, Douglas NJ. Effect of continuous positive airway pressure on sleep architecture in the sleep apnea-hypopnea syndrome: a randomized controlled trial. Am J Respir Crit Care Med. 2001;164:1459–1463
  53. Holman AJ, Depaso WJ. High prevalence of obstructive sleep apnea (OSA) in men with inflammatory arthritis. Arthritis Rheum. 2004;50:S385
  54. Shimizu M, Tachibana N, Nagasaka Y, Goto M. Obstructive sleep apnea (OSA) in RA patients and effect of CPAP on RA activity. Arthritis Rheum. 2003;48:187
  55. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol. 2008;7:563–572
  56. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416–422
  57. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529–534
  58. Lam JC, Ip MS. An update on obstructive sleep apnea and the metabolic syndrome. Curr Opin Pulm Med. 2007;13:484–489
  59. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29–35
  60. Bos JD. de KJ. Effects of etanercept on quality of life, fatigue, and depression in psoriasis. Lancet. 2006;367:6–7
  61. Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicenter study. Ann Rheum Dis. 2007;66:1038–1042
  62. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trial. Ann Rheum Dis. 2007;66:163–168
  63. Lavidor M, Weller A, Babkoff H. How sleep is related to fatigue. Br J Health Psychol. 2003;8:95–105
  64. Majer M, Jones JF, Unger ER, Youngblood LS, Decker MJ, Gurbaxani B, et al. Perception versus polysomnographic assessment of sleep in CFS and non-fatigued control subjects: results from a population-based study. BMC Neurol. 2007;7:40
  65. Zalewska A, Glowacka E, Wyczolkowska J, Tchorzewski H, Narbutt J, Sysa-Jedrzejowska A. Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis. Mediators Inflamm. 2006;2006:81767
  66. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry. 2008;23:421–429
  67. Adler UC, Marques AH, Calil HM. Inflammatory aspects of depression. Inflamm Allergy Drug Targets. 2008;7:19–23
  68. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1044–1053
  69. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett. 2008;29:287–291
  70. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine. 2004;28:87–91
  71. Alberti A, Sarchielli P, Gallinella E, Floridi A, Floridi A, Mazzotta G, et al. Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res. 2003;12:305–311
  72. Coutaux A, Adam F, Willer JC, Le BD. Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine. 2005;72:359–371
  73. Darsow U, Scharein E, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumor necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol. 1997;137:415–417
  74. Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin HM, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism. 2002;51:887–892
  75. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab. 2004;89:4409–4413
  76. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006;31:251–272
  77. Reich A, Orda A, Wisnicka B, Szepietowski JC. Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol. 2007;16:421–428
  78. Bondy B, Baghai TC, Minov C, Schule C, Schwarz MJ, Zwanzger P, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry. 2003;53:538–542
  79. Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology. 2002;27:1041–1049
  80. Ursavas A, Karadag M, Ilcol YO, Burgazlioglu B, Ercan I, Gozu RO. Relationship between serum substance P levels and daytime sleepiness in obstructive sleep apnea syndrome. Chest. 2007;131:1400–1405
  81. Choi EH, Brown BE, Crumrine D, Chang S, Man MQ, Elias PM, et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol. 2005;124:587–595

 Funding for manuscript development was provided by Abbott Laboratories. The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, LP.

 Disclosure: Dr Goldblum is an employee of Abbott Laboratories and owns Abbott stock. Dr McCall has served as an investigator for GlaxoSmithKline, Mini Mitter, the National Institutes of Health, Sanofi-Aventis, Sealy, Sepracor, and Somaxon, receiving research grants; has served as a consultant for AstraZeneca, Orexo AB, Sepracor, and Somaxon, receiving honoraria; and has served as a member of the speakers' bureaus for Sanofi-Aventis and Sepracor, receiving honoraria. Dr Feldman has served as an advisory board member, investigator, and speaker for Abbott Laboratories, Astellas, Galderma, Steifel, and Warner Chilcott, receiving grants and honoraria; has served on the advisory board for Photomedex, receiving stock options; has been an investigator and speaker for Amgen, Centocor, and Genentech, receiving grants and honoraria; and has served as an advisory board member and speaker for the National Psoriasis Foundation, receiving honoraria. Ms Gowda has no conflicts to declare.

 Reprints not available from the author.

PII: S0190-9622(09)00886-X

doi: 10.1016/j.jaad.2009.07.003

Journal of the American Academy of Dermatology
Volume 63, Issue 1 , Pages 114-123 , July 2010

Article Tools

* Image Usage & Resolution